We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+47.58%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$479M
AUM Growth
+$22.5M
Cap. Flow
-$140M
Cap. Flow %
-29.22%
Top 10 Hldgs %
99.57%
Holding
15
New
1
Increased
–
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$2.34M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$65.7M
2
BBIO icon
BridgeBio Pharma
BBIO
+$65.6M
3
NUVB icon
Nuvation Bio
NUVB
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.9B
$389M 81.29%
5,089,611
-1,000,000
-16% -$65.6M
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$2.02B
$27.7M 5.78%
1,316,806
– –
GLUE icon
3
Monte Rosa Therapeutics
GLUE
$2.07B
$23.1M 4.82%
1,472,331
– –
BCAX
4
Bicara Therapeutics
BCAX
$1.82B
$9.57M 2%
568,919
– –
CMPS
5
Compass Pathways
CMPS
$1.67B
$8.27M 1.73%
1,198,418
– –
BBOT
6
BridgeBio Oncology
BBOT
$686M
$7.07M 1.48%
564,625
– –
CALC icon
7
CalciMedica
CALC
$11.6M
$3.43M 0.72%
521,114
– –
SRRK icon
8
Scholar Rock
SRRK
$6.33B
$3.39M 0.71%
77,031
– –
BMEA icon
9
Biomea Fusion
BMEA
$92.5M
$2.54M 0.53%
2,048,757
– –
URGN icon
10
UroGen Pharma
URGN
$1.96B
$2.53M 0.53%
+108,000
New +$2.34M
ACRS icon
11
Aclaris Therapeutics
ACRS
$793M
$1.31M 0.27%
434,455
– –
MRKR icon
12
Marker Therapeutics
MRKR
$21.8M
$485K 0.1%
325,370
– –
OKUR
13
OnKure Therapeutics
OKUR
$170M
$257K 0.05%
88,607
– –
NUVB icon
14
Nuvation Bio
NUVB
$2.02B
– –
-2,960,659
Closed -$11M
VRNA
15
DELISTED
Verona Pharma
VRNA
– –
-615,352
Closed -$65.7M

Similar funds

PCMC
Paragon Capital Management (Colorado) Denver, Colorado $476M AUM 23.92% 1-Year Est. Return
BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
JSC
Jackson Square Capital San Francisco, California $477M AUM 78.87% 1-Year Est. Return
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return

Aisling Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Aisling Capital Management held 15 positions worth $479M, up 4.9% from $456M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Aisling Capital Management withdrew a net $140M in Q4 2025, closing 2 positions and reducing 1 holding. Its most notable exit was Verona Pharma, an estimated $65.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Aisling Capital Management opened a new position in UroGen Pharma worth $2.53M.

  • Aisling Capital Management's largest Q4 2025 buy was UroGen Pharma: 108,000 shares worth $2.53M.
  • Aisling Capital Management's biggest Q4 2025 reduction was BridgeBio Pharma, cutting an estimated $65.6M.
  • Aisling Capital Management fully exited Verona Pharma in Q4 2025, selling an estimated $65.7M.
  • Aisling Capital Management's ten largest holdings make up 100% of its $479M portfolio in Q4 2025.
  • Aisling Capital Management opened 1 new position and closed 2 in Q4 2025.
  • Aisling Capital Management's portfolio value rose 4.9% quarter-over-quarter to $479M.

Based on Aisling Capital Management's 13F filing for Q4 2025, filed 10 Feb 2026.